wanyu/IteraTeR_v2 huggingface dataset:
Original:  The National Institute for Pharmaceutical Technology and Education (NIPTE) is a non-profit scientific and research and development organization that was established in 2005 and incorporated in June 2007 in the State of Indiana.
Revised: About The National Institute for Pharmaceutical Technology and Education (NIPTE) is a non-profit scientific and research and development organization that was established in 2005 and incorporated in June 2007 in the State of Indiana.
Edit intent: style
Original:  The National Institute for Pharmaceutical Technology and Education (NIPTE) is a non-profit scientific and research and development organization that was established in 2005 and incorporated in June 2007 in the State of Indiana.
Revised:  The National Institute for Pharmaceutical Technology and Education (NIPTE) is a non-profit scientific and research and development organization that was established in 2005 and incorporated in June 2007 in the State of URL
Edit intent: style
Original:  Its offices are currently located in Minneapolis, MN.  Education and certification  Board of Directors Faculty Leadership 
Revised:  Its offices are currently located in Minneapolis, URL Education and certification Board of Directors Faculty Leadership 
Edit intent: fluency
Original: About The National Institute for Pharmaceutical Technology and Education URL is a non-profit scientific and research and development organization that was established in 2005 and incorporated in June 2007 in the State of URL Its offices are currently located in Minneapolis, URL NIPTE’s strength comes from its collaboration with top schools of pharmacy, engineering and medicine, and industry and government from across the globe.
Revised:  The National Institute for Pharmaceutical Technology and Education URL is a non-profit scientific and research and development organization that was established in 2005 and incorporated in June 2007 in the State of URL Its offices are currently located in Minneapolis, URL NIPTE’s strength comes from its collaboration with top schools of pharmacy, engineering and medicine, and industry and government from across the globe.
Edit intent: clarity
Original: About The National Institute for Pharmaceutical Technology and Education URL is a non-profit scientific and research and development organization that was established in 2005 and incorporated in June 2007 in the State of URL Its offices are currently located in Minneapolis, URL NIPTE’s strength comes from its collaboration with top schools of pharmacy, engineering and medicine, and industry and government from across the globe.
Revised: About The National Institute for Pharmaceutical Technology and Education (NIPTE) is a non-profit scientific and research and development organization that was established in 2005 and incorporated in June 2007 in the State of URL Its offices are currently located in Minneapolis, URL NIPTE’s strength comes from its collaboration with top schools of pharmacy, engineering and medicine, and industry and government from across the globe.
Edit intent: clarity
Original: About The National Institute for Pharmaceutical Technology and Education URL is a non-profit scientific and research and development organization that was established in 2005 and incorporated in June 2007 in the State of URL Its offices are currently located in Minneapolis, URL NIPTE’s strength comes from its collaboration with top schools of pharmacy, engineering and medicine, and industry and government from across the globe.
Revised: About The National Institute for Pharmaceutical Technology and Education URL is a non-profit scientific and research and development organization that was established in 2005 and incorporated in June 2007 in the State of URL Its offices are currently located in Minneapolis, Minnesota. NIPTE’s strength comes from its collaboration with top schools of pharmacy, engineering and medicine, and industry and government from across the globe.
Edit intent: fluency
Original:  There are currently 18 member universities - each with a seat on the board and a voice in shaping the direction of       the organization   . Key initiatives Education and certification Conferences and events Leadership Board of Directors Faculty Leadership Sources  
Revised:  There are currently 18 member universities - each with a seat on the board and a voice in shaping the direction of the organization Research agenda NIPTE’s goal is to increase science and engineering-based understanding of this area such that novel state-of-the-art technologies can be developed and science-based regulations can be implemented. These technologies will also enable new drug discoveries to be brought to market faster with less variability, higher predictability of performance and at a significantly lower cost. NIPTE’s research agenda is to conduct fundamental and basic research that will: Develop science‐based understanding of pharmaceutical materials, their processing characteristics and performance in manufacturing; Create innovative engineering tools needed to develop, design and scale up cost novel effective processes for the manufacturing of active pharmaceutical ingredients (API); Develop model‐predictive approaches for drug product formulation and manufacturing process design; Create novel manufacturing technologies that allow flexible and cost effective manufacturing of multiple products in the same production line or continuously, to replace current dedicated, largely batch‐wise operated lines; Invent and demonstrate new sensing and control technologies that allow critical product and process variables to be monitored continuously and controlled automatically in order to dramatically reduce current, wasteful reliance on quality control via end of production testing and off‐spec rejection; Create an educational model that synergistically integrates and intimately combines core concepts and methods from Pharmaceutical Sciences and Engineering, with input from Chemistry and Materials Science, to train professionals capable of facilitating systematic product design, process understanding, optimization, and control; Create and deliver educational and training programs that will prepare the technical cadre needed by the industry and the FDA to implement and regulate these new technologies . Key initiatives Education and certification Conferences and events Leadership Board of Directors Faculty Leadership Sources 
Edit intent: clarity
Original:  There are currently 18 member universities - each with a seat on the board and a voice in shaping the direction of       the organization   . Key initiatives Education and certification Conferences and events Leadership Board of Directors Faculty Leadership Sources  
Revised:  There are currently 18 member universities - each with a seat on the board and a voice in shaping the direction of the organization . Key initiatives Education and certification Conferences and events Leadership Board of Directors Faculty Leadership References 
Edit intent: clarity
Original: NIPTE ’ s current membership includes 18 leading schools and colleges of pharmacy and chemical engineering from the following universities:
Revised: NIPTE ' s current membership includes 18 leading schools and colleges of pharmacy and chemical engineering from the following universities:
Edit intent: fluency
Original:  They were keen on “making” what they “sold” because it provided them with more control of the quality of their products.
Revised:  They were keen on "making" what they "sold" because it provided them with more control of the quality of their products.
Edit intent: fluency
Original:  Once the new drug discovery is made, product development and manufacturing are left to traditional “ tried and true ” practices.
Revised:  Once the new drug discovery is made, product development and manufacturing are left to traditional " tried and true ” practices.
Edit intent: fluency
Original:  Once the new drug discovery is made, product development and manufacturing are left to traditional “ tried and true ” practices.
Revised:  Once the new drug discovery is made, product development and manufacturing are left to traditional “ tried and true " practices.
Edit intent: fluency
Original:  Research agenda NIPTE ’ s goal is to increase science and engineering-based understanding of this area such that novel state-of-the-art technologies can be developed and science-based regulations can be implemented.
Revised:  Research agenda NIPTE ' s goal is to increase science and engineering-based understanding of this area such that novel state-of-the-art technologies can be developed and science-based regulations can be implemented.
Edit intent: fluency
Original:  NIPTE ’ s research agenda is to conduct fundamental and basic research that will: Develop science‐based understanding of pharmaceutical materials, their processing characteristics and performance in manufacturing;
Revised:  NIPTE ' s research agenda is to conduct fundamental and basic research that will: Develop science‐based understanding of pharmaceutical materials, their processing characteristics and performance in manufacturing;
Edit intent: fluency
Original:  NIPTE ’ s membership includes leading schools and colleges of pharmacy and chemical and pharmaceutical engineering, and has overlapping scientific interests with pharmaceutical scientists (e.g. American Association of Pharmaceutical Sciences).
Revised:  NIPTE ' s membership includes leading schools and colleges of pharmacy and chemical and pharmaceutical engineering, and has overlapping scientific interests with pharmaceutical scientists (e.g. American Association of Pharmaceutical Sciences).
Edit intent: fluency
Original:  Education agenda Current academic programs in pharmaceutical technology are disappearing despite the continued and growing needs of today ’ s industry leading to too few good teacher/mentors and very few qualified graduates.
Revised:  Education agenda Current academic programs in pharmaceutical technology are disappearing despite the continued and growing needs of today ' s industry leading to too few good teacher/mentors and very few qualified graduates.
Edit intent: fluency
Original:  NIPTE comprises leading educational institutions in the pharmaceutical science and engineering, NIPTE ’ s goal is to create a “pipeline” of diverse talent that commences at the undergraduate level and continues throughout graduate, postgraduate, and continuing education, augmenting the available workforce in academia, industry, and government.
Revised:  NIPTE comprises leading educational institutions in the pharmaceutical science and engineering, NIPTE ' s goal is to create a “pipeline” of diverse talent that commences at the undergraduate level and continues throughout graduate, postgraduate, and continuing education, augmenting the available workforce in academia, industry, and government.
Edit intent: fluency
Original:  NIPTE comprises leading educational institutions in the pharmaceutical science and engineering, NIPTE ’ s goal is to create a “pipeline” of diverse talent that commences at the undergraduate level and continues throughout graduate, postgraduate, and continuing education, augmenting the available workforce in academia, industry, and government.
Revised:  NIPTE comprises leading educational institutions in the pharmaceutical science and engineering, NIPTE ’ s goal is to create a "pipeline" of diverse talent that commences at the undergraduate level and continues throughout graduate, postgraduate, and continuing education, augmenting the available workforce in academia, industry, and government.
Edit intent: fluency
Original:  Rodolfo J. Romanach, “ Research initiatives to support science-based pharmaceutical manufacturing ” , Pharmaceutical Technology, October 1, 2008 Ed Silverman, “ Troubles With Manufacturing: Prabir Basu Explains ” , Pharmalot, November 14, 2008 Prabir Basu, “Today’ s Hidden Crisis in Health Care: the State of Pharmaceutical Manufacturing ” The RPM Report, September 2008, Vol. 3, No. 14 Patrick Kager, David Williams, “ How Do You Solve a Problem Like Manufacturing?
Revised:  Rodolfo J. Romanach, " Research initiatives to support science-based pharmaceutical manufacturing ” , Pharmaceutical Technology, October 1, 2008 Ed Silverman, “ Troubles With Manufacturing: Prabir Basu Explains ” , Pharmalot, November 14, 2008 Prabir Basu, “Today’ s Hidden Crisis in Health Care: the State of Pharmaceutical Manufacturing ” The RPM Report, September 2008, Vol. 3, No. 14 Patrick Kager, David Williams, “ How Do You Solve a Problem Like Manufacturing?
Edit intent: fluency
Original:  Rodolfo J. Romanach, “ Research initiatives to support science-based pharmaceutical manufacturing ” , Pharmaceutical Technology, October 1, 2008 Ed Silverman, “ Troubles With Manufacturing: Prabir Basu Explains ” , Pharmalot, November 14, 2008 Prabir Basu, “Today’ s Hidden Crisis in Health Care: the State of Pharmaceutical Manufacturing ” The RPM Report, September 2008, Vol. 3, No. 14 Patrick Kager, David Williams, “ How Do You Solve a Problem Like Manufacturing?
Revised:  Rodolfo J. Romanach, “ Research initiatives to support science-based pharmaceutical manufacturing " , Pharmaceutical Technology, October 1, 2008 Ed Silverman, “ Troubles With Manufacturing: Prabir Basu Explains ” , Pharmalot, November 14, 2008 Prabir Basu, “Today’ s Hidden Crisis in Health Care: the State of Pharmaceutical Manufacturing ” The RPM Report, September 2008, Vol. 3, No. 14 Patrick Kager, David Williams, “ How Do You Solve a Problem Like Manufacturing?
Edit intent: fluency
Original:  Rodolfo J. Romanach, “ Research initiatives to support science-based pharmaceutical manufacturing ” , Pharmaceutical Technology, October 1, 2008 Ed Silverman, “ Troubles With Manufacturing: Prabir Basu Explains ” , Pharmalot, November 14, 2008 Prabir Basu, “Today’ s Hidden Crisis in Health Care: the State of Pharmaceutical Manufacturing ” The RPM Report, September 2008, Vol. 3, No. 14 Patrick Kager, David Williams, “ How Do You Solve a Problem Like Manufacturing?
Revised:  Rodolfo J. Romanach, “ Research initiatives to support science-based pharmaceutical manufacturing ” , Pharmaceutical Technology, October 1, 2008 Ed Silverman, " Troubles With Manufacturing: Prabir Basu Explains ” , Pharmalot, November 14, 2008 Prabir Basu, “Today’ s Hidden Crisis in Health Care: the State of Pharmaceutical Manufacturing ” The RPM Report, September 2008, Vol. 3, No. 14 Patrick Kager, David Williams, “ How Do You Solve a Problem Like Manufacturing?
Edit intent: fluency
Original:  Rodolfo J. Romanach, “ Research initiatives to support science-based pharmaceutical manufacturing ” , Pharmaceutical Technology, October 1, 2008 Ed Silverman, “ Troubles With Manufacturing: Prabir Basu Explains ” , Pharmalot, November 14, 2008 Prabir Basu, “Today’ s Hidden Crisis in Health Care: the State of Pharmaceutical Manufacturing ” The RPM Report, September 2008, Vol. 3, No. 14 Patrick Kager, David Williams, “ How Do You Solve a Problem Like Manufacturing?
Revised:  Rodolfo J. Romanach, “ Research initiatives to support science-based pharmaceutical manufacturing ” , Pharmaceutical Technology, October 1, 2008 Ed Silverman, “ Troubles With Manufacturing: Prabir Basu Explains " , Pharmalot, November 14, 2008 Prabir Basu, “Today’ s Hidden Crisis in Health Care: the State of Pharmaceutical Manufacturing ” The RPM Report, September 2008, Vol. 3, No. 14 Patrick Kager, David Williams, “ How Do You Solve a Problem Like Manufacturing?
Edit intent: fluency
Original:  Rodolfo J. Romanach, “ Research initiatives to support science-based pharmaceutical manufacturing ” , Pharmaceutical Technology, October 1, 2008 Ed Silverman, “ Troubles With Manufacturing: Prabir Basu Explains ” , Pharmalot, November 14, 2008 Prabir Basu, “Today’ s Hidden Crisis in Health Care: the State of Pharmaceutical Manufacturing ” The RPM Report, September 2008, Vol. 3, No. 14 Patrick Kager, David Williams, “ How Do You Solve a Problem Like Manufacturing?
Revised:  Rodolfo J. Romanach, “ Research initiatives to support science-based pharmaceutical manufacturing ” , Pharmaceutical Technology, October 1, 2008 Ed Silverman, “ Troubles With Manufacturing: Prabir Basu Explains ” , Pharmalot, November 14, 2008 Prabir Basu, "Today' s Hidden Crisis in Health Care: the State of Pharmaceutical Manufacturing ” The RPM Report, September 2008, Vol. 3, No. 14 Patrick Kager, David Williams, “ How Do You Solve a Problem Like Manufacturing?
Edit intent: fluency
Original:  Rodolfo J. Romanach, “ Research initiatives to support science-based pharmaceutical manufacturing ” , Pharmaceutical Technology, October 1, 2008 Ed Silverman, “ Troubles With Manufacturing: Prabir Basu Explains ” , Pharmalot, November 14, 2008 Prabir Basu, “Today’ s Hidden Crisis in Health Care: the State of Pharmaceutical Manufacturing ” The RPM Report, September 2008, Vol. 3, No. 14 Patrick Kager, David Williams, “ How Do You Solve a Problem Like Manufacturing?
Revised:  Rodolfo J. Romanach, “ Research initiatives to support science-based pharmaceutical manufacturing ” , Pharmaceutical Technology, October 1, 2008 Ed Silverman, “ Troubles With Manufacturing: Prabir Basu Explains ” , Pharmalot, November 14, 2008 Prabir Basu, “Today’ s Hidden Crisis in Health Care: the State of Pharmaceutical Manufacturing " The RPM Report, September 2008, Vol. 3, No. 14 Patrick Kager, David Williams, “ How Do You Solve a Problem Like Manufacturing?
Edit intent: fluency
Original:  Rodolfo J. Romanach, “ Research initiatives to support science-based pharmaceutical manufacturing ” , Pharmaceutical Technology, October 1, 2008 Ed Silverman, “ Troubles With Manufacturing: Prabir Basu Explains ” , Pharmalot, November 14, 2008 Prabir Basu, “Today’ s Hidden Crisis in Health Care: the State of Pharmaceutical Manufacturing ” The RPM Report, September 2008, Vol. 3, No. 14 Patrick Kager, David Williams, “ How Do You Solve a Problem Like Manufacturing?
Revised:  Rodolfo J. Romanach, “ Research initiatives to support science-based pharmaceutical manufacturing ” , Pharmaceutical Technology, October 1, 2008 Ed Silverman, “ Troubles With Manufacturing: Prabir Basu Explains ” , Pharmalot, November 14, 2008 Prabir Basu, “Today’ s Hidden Crisis in Health Care: the State of Pharmaceutical Manufacturing ” The RPM Report, September 2008, Vol. 3, No. 14 Patrick Kager, David Williams, " How Do You Solve a Problem Like Manufacturing?
Edit intent: fluency
Original:  ” Pharmaceutical Executive, September 1, 2008
Revised:  " Pharmaceutical Executive, September 1, 2008
Edit intent: fluency
Original: Two Bushmen While it is clear that from the 1990s until the death of Gregory Jacobs in 2014, two World Famous Bushmen operated on Fisherman's Wharf both as a team and as separate acts, sources differ as to whether Jacobs or Johnson was first to come up with the act.
Revised: Two Bushmen From the 1990s until the death of Gregory Jacobs in 2014, two World Famous Bushmen operated on Fisherman's Wharf both as a team and as separate acts, sources differ as to whether Jacobs or Johnson was first to come up with the act.
Edit intent: coherence
Original: Two Bushmen While it is clear that from the 1990s until the death of Gregory Jacobs in 2014, two World Famous Bushmen operated on Fisherman's Wharf both as a team and as separate acts, sources differ as to whether Jacobs or Johnson was first to come up with the act.
Revised: Two Bushmen While it is clear that from the 1990s until the death of Gregory Jacobs in 2014, two World Famous Bushmen operated on Fisherman's Wharf both as a team and as separate acts, each claiming to be the first to come up with the act.
Edit intent: clarity
Original:  However, the San Francisco Chronicle reports that Johnson was the original Bushman, joined by Jacobs in the 1990s.
Revised:  However, San Francisco Chronicle reports that Johnson was the original Bushman, joined by Jacobs in the 1990s.
Edit intent: fluency
Original:  Expansion Samori's campaign swept first through his neighbors, the Bérété and the Cissé, and then into the Wassoulou region (the border of today's Guinea and Mali).
Revised: History Expansion Samori's campaign swept first through his neighbors, the Bérété and the Cissé, and then into the Wassoulou region (the border of today's Guinea and Mali).
Edit intent: coherence
Original: History Expansion Samori's campaign swept first through his neighbors, the Bérété and the Cissé, and then into the Wassoulou region (the border of today's Guinea and Mali).
Revised:  Expansion Samori's campaign swept first through his neighbors, the Bérété and the Cissé, and then into the Wassoulou region (the border of today's Guinea and Mali).
Edit intent: coherence
Original:   Rubin H. Contact interactions between cells that suppress neoplastic development: can they also explain metastatic dormancy?
Revised:  References Rubin H. Contact interactions between cells that suppress neoplastic development: can they also explain metastatic dormancy?
Edit intent: fluency
Original: \r%DIFDELCMD < \n%%% \r%DIFDELCMD < \n %DIFDELCMD < %DIFDELCMD < %%% Contact Normalization is a process by which intercellular junctions mediate signals that allow normal cells to inhibit the transformed growth of neighboring tumor cells.
Revised: %DIFDELCMD < \n%%% \r%DIFDELCMD < \n %DIFDELCMD < %DIFDELCMD < %%% Contact Normalization is a process by which intercellular junctions mediate signals that allow normal cells to inhibit the transformed growth of neighboring tumor cells.
Edit intent: fluency
Original: \r%DIFDELCMD < \n%%% \r%DIFDELCMD < \n %DIFDELCMD < %DIFDELCMD < %%% Contact Normalization is a process by which intercellular junctions mediate signals that allow normal cells to inhibit the transformed growth of neighboring tumor cells.
Revised: \r%DIFDELCMD < \n%%% %DIFDELCMD < \n %DIFDELCMD < %DIFDELCMD < %%% Contact Normalization is a process by which intercellular junctions mediate signals that allow normal cells to inhibit the transformed growth of neighboring tumor cells.
Edit intent: fluency
Original: References Rubin H. Contact interactions between cells that suppress neoplastic development: can they also explain metastatic dormancy?
Revised: Further reading Rubin H. Contact interactions between cells that suppress neoplastic development: can they also explain metastatic dormancy?
Edit intent: clarity
Original:  Adv Cancer Res 2008;
Revised:  Adv Cancer Res .
Edit intent: coherence
Original:  Proc Natl Acad Sci U S A 2008;
Revised:  Proc Natl Acad Sci U S A .
Edit intent: coherence
Original:  These include podoplanin (PDPN), vascular endothelial growth factor receptor 2/kinase insert domain receptor ( VEFR2 /KDR), and transmembrane protein 163 (TMEM163) receptors.
Revised:  These include podoplanin (PDPN), vascular endothelial growth factor receptor 2/kinase insert domain receptor ( VEGFR2 /KDR), and transmembrane protein 163 (TMEM163) receptors.
Edit intent: fluency
Original:  Instead, appeals were made to the Portuguese government, which had been driven out of Portugal the year before during the Peninsular War and was resident in Brazil  .
Revised:  Instead, appeals were made to the Portuguese government, which had fled Portugal the year before during the Peninsular War and was resident in Brazil .
Edit intent: clarity
Original:  After Napoleon's abdication in 1814, it was decided to return it to French control, but it was only on 8 November 1817, when a French expedition arrived with Cayenne's new governor, Claude Carra Saint-Cyr, that the French took formal possession of the territory.
Revised:  After Napoleon's abdication in 1814, it was decided the colony would be returned to French control, but it was only on 8 November 1817, when a French expedition arrived with Cayenne's new governor, Claude Carra Saint-Cyr, that the French took formal possession of the territory.
Edit intent: clarity